Tags

Type your tag names separated by a space and hit enter

Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Viruses. 2022 01 28; 14(2)V

Abstract

This study compared the immunogenicity of inactivated SARS-CoV-2 vaccines between people living with HIV (PLWH) and HIV-negative individuals. We recruited 120 PLWH and 53 HIV-negative individuals aged 18-59 years who had received an inactivated SARS-CoV-2 vaccine in two Chinese cities between April and June 2021. Blood samples were tested for immunogenicity of the inactivated SARS-CoV-2 vaccines. The prevalence and severity of adverse events associated with SARS-CoV-2 vaccines were similar between PLWH and HIV-negative individuals. The seropositivity of neutralizing activity against authentic SARS-CoV-2, of the total amount of antibody (total antibody) and of S-IgG were 71.3%, 81.9%, and 92.6%, respectively, among fully vaccinated PLWH. Among all participants, PLWH had lower neutralizing activity, total antibody, S-IgG, and T-cell-specific immune response levels, compared to HIV-negative individuals, after controlling for types of vaccine, time interval between first and second dose, time after receiving the second dose, and sociodemographic factors. PLWH with a longer interval since HIV diagnosis, who received their second dose 15-28 days prior to study commencement, and who had an interval of ≥21 days between first and second dose had higher neutralizing activity levels. The immunogenicity of the inactivated SARS-CoV-2 vaccines was lower among PLWH as compared to HIV-negative individuals. Vaccination guideline specific for PLWH should be developed.

Links

PMC Free PDF

Authors+Show Affiliations

Huang X
Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Yan Y
National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Su B
Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Xiao D
Rainbow Clinic of Beijing Jingcheng Skin Hospital, Beijing 100101, China.
Yu M
Department of AIDS/STD Control and Prevention, Tianjin Center for Disease Control and Prevention, Tianjin 300011, China.
Jin X
AIDS Healthcare Foundation (AHF), Beijing 100088, China.
Duan J
Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zhang X
Department of Public Health, The University of Tennessee, Knoxville, TN 37996, USA.
Zheng S
Department of Biostatistics and Epidemiology, East Tennessee State University, Johnson City, TN 70300, USA.
Fang Y
Department of Health and Physical Education, The Education University of Hong Kong, Hong Kong 200092, China.
Zhang T
Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Tang W
University of North Carolina Project-China, Guangzhou 510095, China.
Wang L
National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Wang Z
JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 666888, China.
Xu J
Clinical Research Academy, Peking University Shenzhen Hospital, Peking University, Shenzhen 518036, China.

MeSH

AdolescentAdultAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesChinaCross-Sectional StudiesFemaleHIV InfectionsHumansImmunogenicity, VaccineMaleMiddle AgedSARS-CoV-2VaccinationVaccines, InactivatedYoung Adult

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35215870

Citation

Huang, Xiaojie, et al. "Comparing Immune Responses to Inactivated Vaccines Against SARS-CoV-2 Between People Living With HIV and HIV-Negative Individuals: a Cross-Sectional Study in China." Viruses, vol. 14, no. 2, 2022.
Huang X, Yan Y, Su B, et al. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China. Viruses. 2022;14(2).
Huang, X., Yan, Y., Su, B., Xiao, D., Yu, M., Jin, X., Duan, J., Zhang, X., Zheng, S., Fang, Y., Zhang, T., Tang, W., Wang, L., Wang, Z., & Xu, J. (2022). Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China. Viruses, 14(2). https://doi.org/10.3390/v14020277
Huang X, et al. Comparing Immune Responses to Inactivated Vaccines Against SARS-CoV-2 Between People Living With HIV and HIV-Negative Individuals: a Cross-Sectional Study in China. Viruses. 2022 01 28;14(2) PubMed PMID: 35215870.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China. AU - Huang,Xiaojie, AU - Yan,Ying, AU - Su,Bin, AU - Xiao,Dong, AU - Yu,Maohe, AU - Jin,Xia, AU - Duan,Junyi, AU - Zhang,Xiangjun, AU - Zheng,Shimin, AU - Fang,Yuan, AU - Zhang,Tong, AU - Tang,Weiming, AU - Wang,Lunan, AU - Wang,Zixin, AU - Xu,Junjie, Y1 - 2022/01/28/ PY - 2021/12/28/received PY - 2022/01/24/revised PY - 2022/01/26/accepted PY - 2022/2/26/entrez PY - 2022/2/27/pubmed PY - 2022/3/9/medline KW - SARS-CoV-2 IgG antibody KW - antigen-specific T-cell immune response KW - inactivated SARS-CoV-2 vaccines KW - neutralizing activity responses against authentic SARS-CoV-2 KW - people living with HIV KW - self-reported adverse events KW - total antibody specific to SARS-CoV-2 JF - Viruses JO - Viruses VL - 14 IS - 2 N2 - This study compared the immunogenicity of inactivated SARS-CoV-2 vaccines between people living with HIV (PLWH) and HIV-negative individuals. We recruited 120 PLWH and 53 HIV-negative individuals aged 18-59 years who had received an inactivated SARS-CoV-2 vaccine in two Chinese cities between April and June 2021. Blood samples were tested for immunogenicity of the inactivated SARS-CoV-2 vaccines. The prevalence and severity of adverse events associated with SARS-CoV-2 vaccines were similar between PLWH and HIV-negative individuals. The seropositivity of neutralizing activity against authentic SARS-CoV-2, of the total amount of antibody (total antibody) and of S-IgG were 71.3%, 81.9%, and 92.6%, respectively, among fully vaccinated PLWH. Among all participants, PLWH had lower neutralizing activity, total antibody, S-IgG, and T-cell-specific immune response levels, compared to HIV-negative individuals, after controlling for types of vaccine, time interval between first and second dose, time after receiving the second dose, and sociodemographic factors. PLWH with a longer interval since HIV diagnosis, who received their second dose 15-28 days prior to study commencement, and who had an interval of ≥21 days between first and second dose had higher neutralizing activity levels. The immunogenicity of the inactivated SARS-CoV-2 vaccines was lower among PLWH as compared to HIV-negative individuals. Vaccination guideline specific for PLWH should be developed. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/35215870/Comparing_Immune_Responses_to_Inactivated_Vaccines_against_SARS_CoV_2_between_People_Living_with_HIV_and_HIV_Negative_Individuals:_A_Cross_Sectional_Study_in_China_ DB - PRIME DP - Unbound Medicine ER -